within Pharmacolibrary.Drugs.ATC.A;

model A10BH04
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.97,
    Cl             = 0.00026,
    adminDuration  = 600,
    adminMass      = 25 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.417,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.013500000000000002,
    Tlag           = 10.200000000000001
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>A10BH04</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Alogliptin is an oral antihyperglycemic agent, classified as a dipeptidyl peptidase-4 (DPP-4) inhibitor, used in the management of type 2 diabetes mellitus to improve glycemic control. It is approved for adult use and is available as a prescription medication in several countries.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for healthy adult volunteers after single oral dose administration.</p><h4>References</h4><ol><li><p>Karim, A, et al., &amp; Mekki, Q (2010). Pharmacokinetics of alogliptin when administered with food, metformin, or cimetidine: a two-phase, crossover study in healthy subjects. <i>International journal of clinical pharmacology and therapeutics</i> 48(1) 46–58. DOI:<a href=\"https://doi.org/10.5414/cpp48046\">10.5414/cpp48046</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/20040339/\">https://pubmed.ncbi.nlm.nih.gov/20040339</a></p></li><li><p>Dudkowski, C, et al., &amp; Xie, J (2017). The pharmacokinetics and pharmacodynamics of alogliptin in children, adolescents, and adults with type 2 diabetes mellitus. <i>European journal of clinical pharmacology</i> 73(3) 279–288. DOI:<a href=\"https://doi.org/10.1007/s00228-016-2175-1\">10.1007/s00228-016-2175-1</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/27999883/\">https://pubmed.ncbi.nlm.nih.gov/27999883</a></p></li><li><p>Christopher, R, et al., &amp; Karim, A (2008). Pharmacokinetics, pharmacodynamics, and tolerability of single increasing doses of the dipeptidyl peptidase-4 inhibitor alogliptin in healthy male subjects. <i>Clinical therapeutics</i> 30(3) 513–527. DOI:<a href=\"https://doi.org/10.1016/j.clinthera.2008.03.005\">10.1016/j.clinthera.2008.03.005</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/18405789/\">https://pubmed.ncbi.nlm.nih.gov/18405789</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end A10BH04;
